Anzeige
Mehr »
Login
Donnerstag, 24.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
KI-Energiekrise: Wie dieser Small Cap die nukleare Zukunft des Silicon Valley befeuern könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 895036 | ISIN: FR0000053506 | Ticker-Symbol: C7E
Tradegate
23.10.24
11:33 Uhr
12,200 Euro
-0,150
-1,21 %
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
CEGEDIM SA Chart 1 Jahr
5-Tage-Chart
CEGEDIM SA 5-Tage-Chart
RealtimeGeldBriefZeit
12,30012,60020:29
12,40012,45019:48
GlobeNewswire (Europe)
59 Leser
Artikel bewerten:
(0)

Cegedim SA: Revenue growth continued in the third quarter of 2024



PRESS RELEASE

Quarterly financial information as of September 30, 2024
IFRS - Regulated information - Not audited

Cegedim: Revenue growth continued in the third quarter of 2024

  • Revenue of €156.8 million in Q3 2024, up 5.7%
  • Marketing, BPO, HR, and cloud businesses led the way
  • Revenue for the first nine months of 2024 grew 5.9% to €475.8 million

Boulogne-Billancourt, France, October 24, 2024, after the market close.
Revenue

Third quarterChange Q3 2024 / 2023
in millions of euros20242023
reclassified(1)
Reclassification(1)2023
Reported
Reported
vs. reclassified(1)
Like for like(2)(3)
vs. reclassified(1)

Software & Services75.676.0-4.880.8-0.5%-4.2%
Flow23.722.4-0.422.85.5%5.4%
Data & Marketing28.224.10.024.117.0%17.1%
BPO21.619.00.019.013.9%13.9%
Cloud & Support7.76.8+5.21.612.5%12.5%
Cegedim156.8148.30.0148.35.7%3.8%
First 9 monthsChange 9M 2023 / 2022
in millions of euros20242023
reclassified(1)
Reclassification(1)2023
Reported
Reported
vs. reclassified(1)
Like for like(2)(4)
vs. reclassified(1)

Software & Services227.7226.6-15.7242.30.5%-2.6%
Flow73.269.2-1.871.05.7%5.6%
Data & Marketing87.579.00.079.010.8%10.8%
BPO61.551.80.051.818.8%18.8%
Cloud & Support25.822.6+17.55.113.9%13.9%
Cegedim475.8449.30.0449.35.9%4.3%

Cegedim posted consolidated third quarter revenues up 5.7% as reported and 3.8% like for like(2) compared with the same period in 2023. Revenues to end-September rose 5.9% as reported and 4.3% like for like compared with 9M 2023. Marketing, BPO, HR, and cloud businesses all delivered solid growth in the third quarter. As expected, the Software & Services division felt the impact of comparisons with Ségur public health investment spending in 2023 and a slowdown in international sales owing to the decision to refocus the Group's UK doctor software activities on Scotland.
Analysis of business trends by division

Software & Services

Software & ServicesThird quarterChange Q3 2024 / 2023 First 9 monthsChange 9M 2024 / 2023
in millions of euros20242023 reclassified(3)Reported vs. reclassified(1)Like for like(2)
vs.
reclassified(1)
20242023
reclassified(1)
Reported vs. reclassified(1)Like for like(2)
vs.
reclassified(1)
Cegedim Santé20.118.68.0%-6.2%58.958.40.9%-9.8%
Insurance, HR, Pharmacies,
and other services
42.743.9-2.7%-2.7%129.5128.40.9%0.8%
International businesses12.813.5-5.0%-6.1%39.339.8-1.3%-2.8%
Software & Services75.676.0-0.5%-4.2%227.7226.60.5%-2.6%

Revenues at Cegedim Santé grew 8.0% as reported in the third quarter but fell 6.2% like for like. We did not fully meet our 2024 goal of offsetting last year's Ségur impact and keeping like-for-like sales stable, but we are closing the gap with each quarter. Reported growth figures include Visiodent as of March 1, 2024. Visiodent's gradual transition to Cegedim Group products for scheduling, databases, and so on is generating internal sales, which do not appear in the consolidated scope.

Other French subsidiaries had a challenging quarter, with revenues down 2.7%. We saw positive growth at our insurance businesses, thanks to robust project-based sales, and in HR, which is still getting a boost from its client diversification strategy. Conversely, the €2 million in Ségur public health investment subsidies we recorded in Q3 2023 made for a demanding comparison in the pharmacy business, where equipment sales also flagged after accelerating last year.

Internationally, revenues from software sales to UK doctors declined, as expected, following the decision to refocus the activity on Scotland.

Flow

FlowThird quarterChange Q3 2024 / 2023 First 9 monthsChange 9M 2024 / 2023
in millions of euros20242023
reclassified(1)
Reported vs. reclassified(1)Like for like(2)
vs. reclassified(1)
20242023 reclassified(1)Reported vs. reclassified(1)Like for like(2)
vs. reclassified(1)
e-business13.513.5-0.2%-0.4%43.541.35.1%4.8%
Third-party payer10.28.914.3%14.3%29.727.96.7%6.7%
Flow23.722.45.5%5.4%73.269.25.7%5.6%

Third-quarter growth in e-business, e-invoicing, and digitized data exchanges was nearly flat, at -0.2%. Healthcare flows offset a relative slowdown in the Invoicing & Procurement segment, which last year enjoyed sustained growth in France ahead of the e-invoicing reform scheduled to take effect July 1, 2024, but which has since been postponed to September 2026.

The digital data flow business dealing with reimbursement of healthcare payments in France (Third-party payer) experienced 14.3% yoy growth in Q3. It was boosted by strong growth in demand for its fraud and long-term illness detection offerings.

Data & Marketing

Data & MarketingThird quarterChange Q3 2024 / 2023 First 9 monthsChange 9M 2024 / 2023
in millions of euros20242023 reclassified(1)Reported vs. reclassified(1)Like for like(2)
vs. reclassified(1)
20242023 reclassified(1)Reported vs. reclassified(1)Like for like(2)
vs. reclassified(1)
Data15.114.63.4%3.4%43.143.4-0.7%-0.7%
Marketing13.19.538.0%38.0%44.435.624.8%24.8%
Data & Marketing28.224.117.0%17.1%87.579.010.8%10.8%

Data business posted 3.4% yoy growth in the third quarter, resulting in nearly stable growth over nine months. Growth was led by French sales, which were more dynamic than international sales.

The Marketing segment had a record third quarter, up 38% owing to special ad campaigns during the Olympics. The rising popularity of our phygital media offerings in pharmacies helped the segment post 24.8% growth over the first nine months.

BPO

BPOThird quarterChange Q3 2024 / 2023 First 9 monthsChange 9M 2024 / 2023
in millions of euros20242023 reclassified(1)Reported vs. reclassified(1)Like for like(2)
vs. reclassified(1)
20242023 reclassified(1)Reported vs. reclassified(1)Like for like(2)
vs. reclassified
Insurance BPO15.913.815.7%15.7%44.635.924.2%24.2%
Business Services BPO5.75.2+9.2%+9.2%16.915.96.5%6.5%
BPO21.619.013.9%13.9%61.551.818.8%18.8%

The Insurance BPO business grew by more than 15.7% over the third quarter, chiefly owing to its overflow business, which has been flourishing since the start of the year. Growth over nine months amounted to 24.2%, partly thanks to a favorable comparison stemming from the April 1, 2023, launch of the Allianz contract.

Business Services BPO (HR and digitalization) continues to report strong growth, up 9.2% yoy over the quarter on the back of a popular compliance offering and new clients.

Cloud & Support

Cloud & SupportThird quarterChange Q3 2024 / 2023 First 9 monthsChange 9M 2024 / 2023
in millions of euros20242023
reclassified(4)
Reported vs. reclassified(1)Like for like(2)
vs.
reclassified(1)
20242023
reclassified(1)
Reported vs. reclassified(1)Like for like(2)
vs.
reclassified(1)
Cloud & Support7.76.812.5%12.5%25.822.613.9%13.9%

The Cloud & Support division's trajectory continued over the third quarter, with growth of 12.5% reflecting our expanded range of sovereign cloud-backed products and services.

Highlights

Apart from the items cited below, to the best of the company's knowledge, there were no events or changes during Q3 2024 that would materially alter the Group's financial situation.

New financing arrangement

On July 31, 2024, Cegedim announced that it had secured a new financing arrangement consisting of a €230 million syndicated loan. The arrangement is split into €180 million of lines drawn upon closing to refinance the Group's existing debt (RCF and Euro PP, which were to mature in October 2024 and October 2025 respectively) and an additional, undrawn revolving credit facility (RCF) of €50 million. This new financing arrangement will bolster the Group's liquidity and extend the maturity of its debt to, respectively, 5 years (€30 million, payments every six months); 6 years (€60 million, repayable upon maturity); and 7 years (€90 million, repayable upon maturity).

Significant transactions and events post September 30, 2024

To the best of the company's knowledge, there were no post-closing events or changes after September 30, 2024, that would materially alter the Group's financial situation.

Outlook

Based on the currently available information, the Group expects 2024 like-for-like revenue(1) growth to be towards the lower end of the 5-8% range relative to 2023. That said, we still expect recurring operating income to continue to improve.
These targets are not forecasts and may need to be revised if there is a significant worsening of geopolitical, macroeconomic, or currency risks.

---------------

Webcast on October 24, 2024, at 6:15 pm (Paris time)
The webcast is available at: www.cegedim.fr/webcast


The Q3 2024 revenue presentation is available here:
https://www.cegedim.fr/documentation/Pages/presentation.aspx

Financial calendar:

2025January 29 after the close

March 27 after the close

March 28 at 10:00 am

April 24 after the close

June 13 at 9:30

July 24 after the close

September 25 after the close

September 26 at 10:00 am

October 23 after the close
2024 revenue

2024 results

SFAF meeting

Q1 2025 revenue

Shareholders' general meeting

H1 2025 revenue

H1 2025 results

SFAF meeting

Q3 2025 revenue

Financial calendar: https://www.cegedim.fr/finance/agenda/Pages/default.aspx

Disclaimer
This press release is available in French and in English. In the event of any difference between the two versions, the original French version takes precedence. This press release may contain inside information. It was sent to Cegedim's authorized distributor on October 24, 2024, no earlier than 5:45 pm Paris time.
The figures cited in this press release include guidance on Cegedim's future financial performance targets. This forward-looking information is based on the opinions and assumptions of the Group's senior management at the time this press release is issued and naturally entails risks and uncertainty. For more information on the risks facing Cegedim, please refer to Chapter 7, "Risk management", section 7.2, "Risk factors and insurance", and Chapter 3, "Overview of the financial year", section 3.6, "Outlook", of the 2023 Universal Registration Document filled with the AMF on April 3, 2024, under number D.24-0233.

About Cegedim:
Founded in 1969, Cegedim is an innovative technology and services group in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 6,500 people in more than 10 countries and generated revenue of €616 million in 2023.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more please visit: www.cegedim.fr
And follow Cegedim on X: @CegedimGroup, LinkedIn, and Facebook.

Aude Balleydier
Cegedim
Media Relations
and Communications Manager

Tel.: +33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr
Damien Buffet
Cegedim
Head of Financial
Communication

Tel.: +33 (0)7 64 63 55 73
damien.buffet@cegedim.com
Céline Pardo
Becoming RP Agency
Media Relations Consultant


Tel.: +33 (0)6 52 08 13 66
cegedim@becoming-group.com

Annexes

Breakdown of revenue by quarter and division

Year 2024

In € million Q1Q2Q3Q4Total
Software & Services 74.377.875.6 227.7
Flow 25.324.223.7 73.2
Data & Marketing 27.032.328.2 87.5
BPO 20.219.721.6 61.5
Cloud & Support 9.09.17.7 25.8
Group revenue 155.9163.1156.8 475.8

Year 2023

In € million Q1
reclassified
Q2
reclassified
Q3

reclassified
Q4
reclassified
Total
reclassified
Software & Services 74.476.276.0 226.6
Flow 24.022.822.4 69.2
Data & Marketing 24.630.324.1 79.0
BPO 14.418.419.0 51.8
Cloud & Support 8.47.46.8 22.6
Group revenue 145.9155.1148.3 449.4

Breakdown of revenue by geographic zone, currency and division at September 30, 2024

as a % of consolidated revenues Geographic zone Currency
FranceEMEA
ex. France
Americas EuroGBPOther
Software & Services 82.8%17.1%0.1% 86.2%12.0%1.7%
Flow 91.9%8.1%0.0% 94.5%5.5%0.0%
Data & Marketing 97.9%2.1%0.0% 98.0%0.0%2.0%
BPO 100.0%0.0%0.0% 100.0%0.0%0.0%
Cloud & Support 99.9%0.1%0.0% 100.0%0.0%0.0%
Cegedim 90.1%9.8%0.1% 92.2%6.6%1.2%


1 As of January 1, 2024, our Cegedim Outsourcing and Audiprint subsidiaries-which were previously housed in the Software & Services division-as well as BSV-formerly of the Flow division-have been moved to the Cloud & Support division in order to capitalize on operating synergies between cloud activities and IT solutions integration.

2 At constant scope and exchange rates. The positive currency impact of 0.2% was mainly due to the pound sterling. The positive scope effect of 1.8% was attributable to the first-time consolidation in Cegedim's accounts of Visiodent starting March 1, 2024.The positive currency impact of 0.1% was mainly due to the pound sterling. The positive scope effect of 1.4% was attributable to the first-time consolidation in Cegedim's accounts of Visiodent starting March 1, 2024.

3 To take advantage of synergies, Cegedim Outsourcing, Audiprint, and BSV have been reassigned to the Cloud & Support division.At constant scope and exchange rates.

4 To take advantage of synergies, Cegedim Outsourcing, Audiprint, and BSV have been reassigned to the Cloud & Support division.At constant scope and exchange rates.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.